Description

Cosmo Pharmaceuticals N.V. is a specialized pharmaceutical company dedicated to the global development and commercialization of products primarily focused on gastroenterology and endoscopy. Its diverse portfolio features established therapies such as Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, both oral tablet formulations prescribed for inducing remission in active, mild to moderate ulcerative colitis. Innovation in diagnostics is evident with GI Genius, an AI-driven system designed for the detection of colorectal polyps, and Methylene Blue MMX, a diagnostic drug that enhances the identification of precancerous and cancerous colorectal lesions during colonoscopic procedures. For gastrointestinal endoscopic interventions, the company provides Eleview, an injectable solution facilitating the submucosal lift of polyps, adenomas, early-stage cancers, and other mucosal lesions. Aemcolo/Relafalk serves as a pharmaceutical agent addressing a range of conditions, including traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth (SIBO). Beyond its core GI focus, Cosmo also markets Winlevi, an androgen receptor inhibitor for treating acne vulgaris, and Clascoterone, another androgen receptor inhibitor developed for scalp conditions like androgenetic alopecia. The company's offerings further extend to Rifamycin for irritable bowel syndrome with diarrhea (IBS-D), ByFavo (Remimazolam) — a fast-acting intravenous benzodiazepine for procedural sedation — and pipeline assets such as CB-03-10, an oral androgen receptor antagonist targeting solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, presented as a single-use enema formulation. Founded in 1997 and headquartered in Dublin, Ireland, Cosmo Pharmaceuticals N.V. maintains strategic licensing agreements with RedHill Biopharma Ltd. and Acacia Pharma Group plc.